Schuchter, Lynn M.

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., Yu, Z., Yang, J., Wang, B., Sun, H., et al. (2018) · Nature

Cancer Immunotherapy and BiomarkersExtracellular vesicles in disease

Cited by 2,813

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine

Melanoma and MAPK PathwaysColorectal Cancer Treatments and Studies

Cited by 2,810

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 2,434

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 2,156

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 1,664

TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion

Khan, O., Giles, J. R., McDonald, S., Manne, S., Ngiow, S. F., Patel, K. P., Werner, M. T., Huang, A. C., Alexander, K. A., Wu, J. E., et al. (2019) · Nature

T-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers

Cited by 1,646

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., et al. (2016) · Cell

Cancer Immunotherapy and Biomarkersinterferon and immune responses

Cited by 1,216

Targeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma

Ma, X.-H., Piao, S.-F., Dey, S., Mcafee, Q., Karakousis, G., Villanueva, J., Hart, L. S., Levi, S., Hu, J., Zhang, G., et al. (2014) · Journal of Clinical Investigation

Melanoma and MAPK PathwaysAutophagy in Disease and Therapy

Cited by 457

Tumor-associated B-cells induce tumor heterogeneity and therapy resistance

Somasundaram, R., Zhang, G., Fukunaga-Kalabis, M., Perego, M., Krepler, C., Xu, X., Wagner, C., Hristova, D., Zhang, J., Tian, T., et al. (2017) · Nature Communications

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 151

Best Practices for Reducing Unplanned Acute Care for Patients With Cancer

Handley, N. R., Schuchter, L. M., & Bekelman, J. E. (2018) · Journal of Oncology Practice

Emergency and Acute Care StudiesCancer survivorship and care

Cited by 137

Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology

Petrelli, N. J., Winer, E. P., Brahmer, J., Dubey, S., Smith, S., Thomas, C., Vahdat, L. T., Obel, J., Vogelzang, N., Markman, M., et al. (2009) · Journal of Clinical Oncology

Science, Research, and MedicineHealth and Medical Research Impacts

Cited by 121

miR‐200c/Bmi1 axis and epithelial–mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment

Liu, S., Tetzlaff, M. T., Wang, T., Yang, R., Xie, L., Zhang, G., Krepler, C., Xiao, M., Beqiri, M., Xu, W., et al. (2015) · Pigment Cell & Melanoma Research

Melanoma and MAPK PathwaysMicroRNA in disease regulation

Cited by 54

Improving the Safety of Oral Chemotherapy at an Academic Medical Center

Shah, N. N., Casella, E., Capozzi, D., McGettigan, S., Gangadhar, T. C., Schuchter, L., & Myers, J. S. (2016) · Journal of Oncology Practice

Pharmacy and Medical PracticesPharmaceutical Practices and Patient Outcomes

Cited by 33

FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial

Nti, A. A., Serrano, L. W., Sandhu, H. S., Uyhazi, K. E., Edelstein, I. D., Zhou, E. J., Bowman, S., Song, D., Gangadhar, T. C., Schuchter, L. M., et al. (2019) · Retina

Drug-Induced Ocular ToxicityOcular Oncology and Treatments

Cited by 31